Navigation Links
Amigal in Medical Technology

Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease

Agency Supports Amigal Move to Phase 3; Eligible for Accelerated Approval; Final Global Regulatory Plan Expected by Year End CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD ), a biopharmaceutical company developing small molecule, orally-administere...

Amicus Therapeutics Presents Data From Preclinical and Phase 1 Studies of Amigal for Fabry Disease

Studies in Mice Show Reduction of Enzyme Substrate CRANBURY, N.J., March 19, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company...

Amicus Therapeutics Commences Phase 3 Trial Evaluating Amigal(TM) for the Treatment of Fabry Disease

...mpany is eligible to seek Accelerated Approval for amigal according to Subpart H regulations. The Company ha...micus stated, "The start of our Phase 3 trial with amigal is a major milestone for Amicus and highlights our...essful Phase 3 study. We continue to believe that amigal may be an important treatment option for patients ...

Amicus Therapeutics Suspends Enrollment for Phase 2 Clinical Trial of AT2220 for Pompe Disease

...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...

Amicus Therapeutics Announces Positive Progress of Three Lead Clinical Programs and General Outlook for 2009

... Multiple Clinical Milestones throughout the Year; amigal to Initiate Phase 3 Global Development in Second Q...ire HGT), plans to initiate Phase 3 development of amigal for the treatment of Fabry disease in the second q...and CEO. CLINICAL PROGRAM ADVANCEMENTS amigal (migalastat hydrochloride) for the treatment of Fa...

Amicus Therapeutics Announces Second Quarter 2008 Financial Results

...meeting with the FDA related to our development of amigal for the treatment of Fabry Disease," said John F. ...ccessfully completed an End of Phase 2 meeting for amigal with the U.S. Food and Drug Administration (FDA). ...e Company plans to initiate Phase 3 development of amigal in the first half of 2009. In parallel with the ...

Amicus Therapeutics to Present at the 26th Annual JPMorgan Healthcare Conference

...ks and uncertainties inherent in the business of Amicus, including, without limitation: the effect of the completion of the Phase 2 clinical trial for amigal for the treatment of Fabry disease, the plans for the Phase 3 clinical trial for Amigal, the Phase II clinical trials for Plicera(TM) for the treatmen...
Amigal in Biological Technology

Amicus Therapeutics Announces Second Quarter 2009 Financial Results

...cant achievement for Amicus with our lead program, amigal for Fabry disease, entering Phase 3 development." ...sease." Clinical Program Updates amigal (TM) (migalastat hydrochloride) for the treatme...mpany is eligible to seek Accelerated Approval for amigal according to Subpart H regulations. Amicus has beg...

Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting

.... Preliminary Results: Treatment with amigal was generally well-tolerated, with no drug-related...rrhea. Subjects identified as responders to amigal at the completion of the Phase 2 studies continued...he FDA supports a Phase 3 clinical trial comparing amigal to placebo based on a surrogate primary endpoint o...

Publication of Shire plc's Annual Report 2008

...t received the rights to three compounds, PLICERA, amigal and AT2220, in markets outside the US. PLIC...ights to PLICERA in markets outside the US. amigal (HGT-3310 for the treatment Fabry disease) amigal is an orally-administered, small molecule pharmaco...

Amicus Therapeutics Announces Change to Board of Directors

...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...

Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results

...e Company plans to initiate Phase 3 development of amigal for the treatment of Fabry disease in the second q...he FDA supports a Phase 3 clinical trial comparing amigal to placebo based on a surrogate primary endpoint o...al designed to evaluate the safety and efficacy of amigal versus enzyme replacement therapy (ERT) in Fabry p...

Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date

...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...

Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors

...ing lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...

Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference

...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...

Amicus Therapeutics Announces Third Quarter 2008 Financial Results

...yments." Program Advancements Fabry Disease: amigal (migalastat hydrochloride) is an investigational, ...Company expects to initiate Phase 3 development of amigal in the first half of 2009. In addition, 23 of th...s. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducti...

Amicus Therapeutics Announces Third Quarter 2008 Results Release Date

...ting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatm...
Other Tags
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
(Date:3/27/2015)... Florida Hospital is excited to continue its partnership with ... provider for the 2015 and 2016 season. As the Storm’s ... an athletic trainer for the team throughout each season. Tonight, ... the Cleveland Gladiators at Amalie Arena; the game starts at ... us as it gives us the opportunity, to provide health ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 Bleeding ... patients undergoing percutaneous coronary intervention (PCI), resulting in ... observed a “risk-treatment paradox,” in which the highest-risk ... treatment are treated less often with bleeding avoidance ... Saint Luke’s Mid America Heart Institute asked the ...
(Date:3/27/2015)... 2015 On February 21, 2015, ... the Stardust Penthouse on the rooftop of the ... leading sustainable product TV and film placement producer, ... event, which featured some of the world’s top ... and services. , “We were honored to have ...
(Date:3/27/2015)... (PRWEB) March 27, 2015 While deep learning ... 2015 GPU technology conference (GTC) , the CEO of one ... and push the human lifespan well beyond the generally-agreed ceiling ... informatics company , is one of 12 companies recognized as ... other startups in the GTC Emerging Companies Summit ...
Breaking Medicine News(10 mins):Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 2Health News:Florida Hospital Is Kicking off the 2015 Season as the Exclusive Health Care Provider for the Tampa Bay Storm 3Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3Health News:Choices Recovery Releases 'Salute to the Oscars' EcoLuxe Lounge Compilation Video 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 2Health News:InSilico Medicine, Inc. Stands Out from High Tech Startups at 2015 GPU Conference 3
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... , March 12, 2015 WHEN:Tuesday, March ... Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , Frost ... SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 Biometric ... to compete in several different markets and industries. ... currently witnessing an uptrend. Join ...
(Date:3/10/2015)... PROVO, Utah , March 10, 2015   ... genome interpretation, has been selected by next-generation sequencing company ... provider of whole exome and targeted gene panel interpretation. ... sequencing provider, has adopted the most current technologies to ... of genetic research. The company offers two types of ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3
Other Contents